Ontix Partners with Mavenir to Deliver Open RAN Neutral Host In-Building Mobile Connectivity
8.9.2021 10:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Ontix, the UK based next-generation infrastructure-as-a-service provider, will be launching an Open RAN pilot for neutral host in-building connectivity in a central London office building, powered by Mavenir’s MAVair solution.
The Open RAN platform will be deployed at the Ontix Data Centre in London whilst the small cell units will be deployed at an Ontix’s customer building. The solution would enable Ontix to provide indoor mobile connectivity to typical areas like multi-tenanted offices, shopping malls, stadiums, hospitals, enterprise buildings and hot spots, delivering contiguous coverage and high-speed mobile connectivity to its enterprise customers and end consumers.
Delivering high-quality mobile connectivity indoors poses significant challenges to both operators and building owners, with a range of factors including the number of people in a building, construction materials and remote locations all impacting signal strength. It is imperative that any solution must provide service for all users, irrespective of the carrier they happen to be subscribed to, by using neutral host solutions.
Ontix and Mavenir will trial the delivery of a neutral host in-building, Open Virtualised Radio Access Network (Open vRAN) to provide enhanced connectivity. This includes the delivery and integration of Open RAN compatible, software upgradable small cells for enhanced in-building coverage and capacity.
“Open RAN is changing the dynamics of how cellular solutions are designed and delivered, and this deployment is at the cutting edge of the technology in the UK,” said Patrick Bradd, Chief Executive Officer at Ontix. “We are excited to be working on this ground-breaking Open RAN pilot to deploy a neutral host architecture to demonstrate its flexibility and how the use of commoditised hardware, can help to create the next generation of in-building networks.”
“Mavenir is delighted to partner with Ontix in addressing this demand from enterprises and consumers for mobile connectivity, especially in areas with poor indoor and in-building coverage. We are confident that using this innovative vRAN solution Ontix will be able to deliver a cost effective and a higher quality network to meet this growing demand,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
The MAVair family includes Open vRAN designed with cloud-native virtualisation techniques, enabling the RAN to flex and adapt based on usage and coverage. Mavenir’s vRAN platform provides a fully scalable virtualised network architecture with open standard interfaces, providing neutral host solution providers the option of deploying radio units from different vendors. The vRAN platform uses software running on COTS (commercial off the shelf) hardware that provides cost effectiveness, more flexibility and agility to neutral host solution providers, whilst providing one architecture for many different user scenarios.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Ontix:
Ontix is a next-generation infrastructure-as-a-service provider, disrupting the business model for delivering lightning-fast connectivity wherever it is needed. Ontix makes it cheaper, easier and quicker for mobile operators and wireless network providers to add next-generation wireless networks through its turnkey solutions. Ontix is transforming the entire process for wireless network densification by investing in shared small cell infrastructure – including connectivity – and licensing this to operators.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005060/en/
Contact information
PR Contact Mavenir
Emmanuela Spiteri
PR@mavenir.com
EMEA PR
Kevin Taylor
KTaylor@GlobalResultsPR.com
PR Contact Ontix:
Richard Howson
richard.howson@temono.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
